Department of Pharmacology and Pharmacy Practice, K. B. Institute of Pharmaceutical Education and Research, Near Gh-6 circle, Sector-23, Gandhinagar, 382023, Gujarat, India.
Reprod Sci. 2022 Aug;29(8):2282-2298. doi: 10.1007/s43032-022-00933-y. Epub 2022 Apr 27.
Polycystic ovary syndrome (PCOS) is a common cause of female infertility, affecting 5-10% of women of reproductive age. Many studies have reported improvement in insulin resistance and thereby intracellular glucose uptake after myo-inositol treatment in PCOS patients, but these studies have a small sample size, varying methodology, and outcome analysis. Therefore, we designed a present meta-analysis of randomized controlled trials to explore the effect of myo-inositol supplementation on anthropometric, metabolic, and endocrine outcomes in PCOS patients. Randomized controlled trials assessing the effectiveness of myo-inositol were identified in electronic databases like PubMed, Cochrane, Embase, MEDLINE, CINAHL, and AMED. Listed references and citations of related articles were also screened manually to identify additional studies. Research papers for which full-text copies were not available on scientific databases were procured from respective authors. Thereafter, data were extracted from included studies and analyzed using RevMan 5.3 of the Cochrane Collaboration. A total of 17 randomized controlled trials with 1083 PCOS patients were included in this meta-analysis. Among the 17 trials, 7 trials compared myo-inositol with folic acid, 8 trials compared myo-inositol with metformin, and 2 trials compared myo-inositol with oral contraceptives. No significant improvement in body mass index, waist-to-hip ratio, fasting insulin, fasting glucose, HOMA, LH, FSH, estradiol, sex hormone-binding globulin, dehydroepiandrosterone, and total testosterone levels were observed after myo-inositol treatment in PCOS patients except androstenedione and prolactin levels. Clinically significant improvement was not observed in anthropometric, metabolic, and endocrine outcomes after myo-inositol treatment in PCOS patients. However, heterogeneity between studies was high.
多囊卵巢综合征（PCOS）是女性不孕的常见原因，影响着 5-10%的育龄妇女。许多研究报告称，多囊卵巢综合征患者在接受肌醇治疗后，胰岛素抵抗得到改善，从而导致细胞内葡萄糖摄取增加，但这些研究样本量小、方法学不同、结果分析也不同。因此，我们设计了本次荟萃分析，旨在探讨肌醇补充对多囊卵巢综合征患者的人体测量、代谢和内分泌结局的影响。我们在电子数据库（如 PubMed、Cochrane、Embase、MEDLINE、CINAHL 和 AMED）中检索了评估肌醇有效性的随机对照试验。此外，我们还手动筛选了相关文章的参考文献和引文，以确定其他研究。对于无法从科学数据库中获取全文的研究论文，我们从相应的作者处获取了全文。然后，我们从纳入的研究中提取数据，并使用 Cochrane 协作的 RevMan 5.3 进行分析。本次荟萃分析共纳入了 17 项随机对照试验，涉及 1083 名多囊卵巢综合征患者。在这 17 项试验中，有 7 项试验比较了肌醇与叶酸，8 项试验比较了肌醇与二甲双胍，2 项试验比较了肌醇与口服避孕药。在多囊卵巢综合征患者中，肌醇治疗后除了雄烯二酮和催乳素水平外，体重指数、腰臀比、空腹胰岛素、空腹血糖、HOMA、LH、FSH、雌二醇、性激素结合球蛋白、脱氢表雄酮和总睾酮水平均无显著改善。在多囊卵巢综合征患者中，肌醇治疗后在人体测量、代谢和内分泌结局方面没有观察到临床显著改善。但是，研究之间存在高度异质性。
